Global Morpho Pharma SAS is a French company created early 2018 that aims at developing, manufacturing, distributing and selling radionuclides and radiopharmaceuticals under Good Manufacturing Practice (GMP) quality for the benefit of the patients and the expanding nuclear medicine industry. Global Morpho Pharma intends to become one of the major suppliers of pharmaceutical grade doses of therapeutic radiolabeled compounds for the pharmaceutical industry.
In the therapeutic field Global Morpho Pharma anticipates very soon a massive need for high quality pharmaceutical grade radionuclides from alternative sources such as :
Lutetium-177 is a radioactive atom emitting beta particles (in other words electrons) and has the potential to destroy cells over a distance up to one millimeter in average. 177Lu has a half-life of 6.7 days and the quality of the product provided by the company is only non-carrier added (nca), meaning high specific activity and non-contamination with the long half-life impurity 177mLu.
Actinium-225 is a radioactive element emitting alpha particles (more than 7,000 times the size and weight of an electron) that has the potential to ionize strongly, and therefore destroy, over a distance of about the thickness of six cells. When combined with a vector targeting tumor cells, it will be able to kill efficiently but only over a short distance. 225Ac has a half-life of 9.91 days.
These sources need to be qualified and approved by the major authorities in the world and this process is under progress.
The core founding members of Global Morpho Pharma SAS include Dmitriy and Alexander Lintchevsky from the Russian company Komfins Service LLC, Pierre Marie Lemer, Valerie Chevreul and Xavier Gandillot from the French company Lemer Pax and Richard Zimmermann, from the French company Chrysalium Consulting.
LEMER PAX / La chapelle-sur -Erdre, France
SPECTRON / South bend, Indianapolis IN, USA
SCK.CEN / Mol, Belgium